NBT Bank N A NY Has $7.58 Million Position in Merck & Co., Inc. $MRK

NBT Bank N A NY reduced its holdings in Merck & Co., Inc. (NYSE:MRK) by 1.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 95,772 shares of the company’s stock after selling 1,628 shares during the quarter. NBT Bank N A NY’s holdings in Merck & Co., Inc. were worth $7,581,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Peoples Financial Services CORP. grew its position in shares of Merck & Co., Inc. by 0.5% in the second quarter. Peoples Financial Services CORP. now owns 22,778 shares of the company’s stock valued at $1,803,000 after purchasing an additional 122 shares during the last quarter. McLean Asset Management Corp grew its position in shares of Merck & Co., Inc. by 3.7% in the second quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock valued at $292,000 after purchasing an additional 125 shares during the last quarter. Cora Capital Advisors LLC grew its position in shares of Merck & Co., Inc. by 2.4% in the second quarter. Cora Capital Advisors LLC now owns 5,343 shares of the company’s stock valued at $423,000 after purchasing an additional 125 shares during the last quarter. Foundation Wealth Management LLC PA grew its position in shares of Merck & Co., Inc. by 2.4% in the first quarter. Foundation Wealth Management LLC PA now owns 5,361 shares of the company’s stock valued at $481,000 after purchasing an additional 127 shares during the last quarter. Finally, Saiph Capital LLC grew its position in shares of Merck & Co., Inc. by 3.7% in the first quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock valued at $320,000 after purchasing an additional 128 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Down 1.3%

NYSE MRK opened at $87.63 on Wednesday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock’s 50 day moving average is $83.06 and its two-hundred day moving average is $81.53. The company has a market capitalization of $218.89 billion, a price-to-earnings ratio of 13.50, a PEG ratio of 0.91 and a beta of 0.37. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $111.58.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.03 by $0.10. The business had revenue of $15.81 billion during the quarter, compared to analysts’ expectations of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Equities analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, October 7th. Investors of record on Monday, September 15th were given a dividend of $0.81 per share. This represents a $3.24 annualized dividend and a dividend yield of 3.7%. The ex-dividend date was Monday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 49.92%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on MRK shares. Wells Fargo & Company lowered their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Saturday, September 27th. Morgan Stanley decreased their target price on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. Finally, Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their target price for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $104.31.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.